The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Vaccination efficacy in patients with hematological malignancies
Current knowledge on whether vaccines are efficacious in patients with hematological malignancies remain limited. Susanne Saussele, MD, University of Heidelberg, Mannheim, Germany, discusses antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in patients with hematological disorders. Patients who did not produce a sufficient immune response post-vaccination tended to have received Bruton’s tyrosine kinase (BTK) inhibitors such as acalabrutinib or ibrutinib, or immunotherapies such as rituximab. Conversely, all patients with chronic myeloid leukemia (CML) responded well to vaccination. Further research is required to assess the effect of booster vaccines in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
